Drug Profile
Navepegritide - Ascendis Pharma
Alternative Names: ACP-015; C-type natriuretic peptide prodrug - Ascendis Pharma; Navepegritide; Navepegritide- Ascendis Pharma; TransCon C-type natriuretic peptide; TransCon CNPLatest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator Ascendis Pharma
- Developer Ascendis Pharma; VISEN Pharmaceuticals
- Class Natriuretic peptides
- Mechanism of Action C Type natriuretic peptide replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Achondroplasia
Most Recent Events
- 23 Jan 2024 Phase-II clinical trials in Achondroplasia (In infants, In neonates) in Australia (SC) (NCT06079398)
- 11 Jan 2024 Ascendis Pharma files an IND application amendment with the FDA in in USA for phase II reACHin trial in achondroplasia
- 07 Jan 2024 Ascendis Pharma plans to submit New Drug Application to the US FDA for Achondroplasia (In children) in the fourth quarter of 2024